Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8146 to 8160 of 8993 results

  1. Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]

    Discontinued Reference number: GID-TA11108

    Technology appraisal guidance
    Discontinued

  2. Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) [ID622]

    Discontinued Reference number: GID-TAG360

    Technology appraisal guidance
    Discontinued

  3. T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]

    Discontinued Reference number: GID-TAG433

    Technology appraisal guidance
    Discontinued

  4. Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]

    Discontinued Reference number: GID-TAG332

    Technology appraisal guidance
    Discontinued

  5. Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]

    Discontinued Reference number: GID-TAG435

    Technology appraisal guidance
    Discontinued

  6. Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]

    Discontinued Reference number: GID-TAG425

    Technology appraisal guidance
    Discontinued

  7. Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]

    Discontinued Reference number: GID-TAG424

    Technology appraisal guidance
    Discontinued

  8. Lung cancer (non-small cell) - afatinib [ID357]

    Discontinued Reference number: GID-TAG422

    Technology appraisal guidance
    Discontinued

  9. Macular oedema (diabetic) - pegaptanib sodium [ID452]

    Discontinued Reference number: GID-TAG280

    Technology appraisal guidance
    Discontinued

  10. Generalised anxiety disorder - quetiapine [ID347]

    Discontinued Reference number: GID-TAG421

    Technology appraisal guidance
    Discontinued

  11. Venous thromboembolism - apixaban (acute medical illness) [ID310]

    Discontinued Reference number: GID-TAG419

    Technology appraisal guidance
    Discontinued

  12. Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

    Discontinued Reference number: GID-TAG403

    Technology appraisal guidance
    Discontinued

  13. Prostate cancer (prevention) - dutasteride [ID75]

    Discontinued Reference number: GID-TAG409

    Technology appraisal guidance
    Discontinued

  14. Hypercholesterolemia - mipomersen [ID524]

    Discontinued Reference number: GID-TAG437

    Technology appraisal guidance
    Discontinued

  15. Serelaxin for the treatment of acute decompensated heart failure [ID673]

    Discontinued Reference number: GID-TAG454

    Technology appraisal guidance
    Discontinued